Kyverna Therapeutics (KYTX) Current Assets (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Current Assets data on file, last reported at $241.7 million in Q1 2026.

• Quarterly Current Assets fell 2.39% year-over-year to $241.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $241.7 million (down 2.39% YoY) and the FY2025 annual result came in at $283.0 million, down 2.63% from the prior year.
• Current Assets eased to $241.7 million in Q1 2026, from $283.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $375.5 million in Q1 2024 to a low of $60.7 million in Q4 2023.
• A 4-year average of $256.3 million and a median of $265.3 million in 2025 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets jumped 379.03% — and 2025, when it tumbled 46.24%.
• Tracing KYTX's Current Assets over 4 years: stood at $60.7 million in 2023, then surged by 379.03% to $290.6 million in 2024, then dropped by 2.63% to $283.0 million in 2025, then slipped by 14.57% to $241.7 million in 2026.
• The last three Current Assets figures came in at $241.7 million (Q1 2026), $283.0 million (Q4 2025), and $174.9 million (Q3 2025), per Business Quant data.